论文部分内容阅读
目的:研究参松养心胶囊联合美托洛尔片治疗冠心病心律失常的临床疗效。方法 :将近年来某院收治的60例冠心病心律失常患者随机分为联合用药组与美托洛尔组。为美托洛尔组患者单用美托洛尔片进行治疗,为联合用药组患者联用参松养心胶囊与美托洛尔片进行治疗,然后对比分析两组患者的临床疗效。结果 :与美托洛尔组患者相比,联合用药组患者治疗的总有效率较高,差异有统计学意义(X~2=18.72,P<0.05)。与美托洛尔组患者相比,联合用药组患者在进行治疗后其心房颤动、房室交界性期前收缩、室性期前收缩以及房性期前收缩的发生率均较低,差异有统计学意义(P<0.05)。结论 :联合应用参松养心胶囊与美托洛尔治疗冠心病心律失常可取得理想的临床效果,能显著减少患者心房颤动、房室交界性期前收缩、室性期前收缩以及房性期前收缩等心律失常的发生率。
Objective: To study the clinical efficacy of Shensong Yangxin Capsule combined with metoprolol in the treatment of arrhythmia of coronary heart disease. Methods: Sixty patients with coronary heart disease and arrhythmia admitted in a hospital in recent years were randomly divided into combination group and metoprolol group. For the metoprolol group patients with metoprolol tablets alone for the combined treatment group patients with Shensongyangxin capsules and metoprolol tablets for treatment, and then compared the clinical efficacy of the two groups of patients. Results: Compared with metoprolol group, the total effective rate of treatment in combination group was higher, the difference was statistically significant (X ~ 2 = 18.72, P <0.05). Compared with patients in metoprolol group, the incidence of atrial fibrillation, premature atrioventricular junctional contraction, premature ventricular contraction and atrial premature contractions in combination group were lower after treatment Statistical significance (P <0.05). Conclusion: The combined application of Shensong Yangxin Capsule and metoprolol in the treatment of arrhythmia of coronary heart disease can achieve the ideal clinical effect, which can significantly reduce the patient atrial fibrillation, atrioventricular junctional premature rupture, ventricular premature ventricular contraction and atrial Pre-systolic and other arrhythmias.